Apnimed Email Format
Pharmaceutical ManufacturingMassachusetts, United States51-200 Employees
Apnimed is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, focused on developing oral medicines for obstructive sleep apnea and related disorders. Its lead candidate, AD109, is advancing through regulatory review with the aim of future commercialization. The organization operates within the pharmaceutical manufacturing sector, pursuing programs intended to broaden treatment options for sleep-disordered breathing. It participates in the broader sleep medicine community by sharing research at major conferences. In 2026, Apnimed appointed Kevin Lind as chief executive officer, signaling a leadership transition as the company moves toward key development milestones. The firm has a history of collaboration, including a 2023 partnership with Shionogi Inc. that involved a joint venture.